BioVie Inc.
Investors that purchased the Company’s securities and have suffered a loss, please fill in transaction information below, or email to info@portnoylaw.com.
There is no cost or obligation associated with submitting your information. If you are a shareholder who suffered a loss, please submit your contact information and purchase information to participate in the putative class action.
We also encourage you to contact Lesley F. Portnoy of The Portnoy Law Firm, at 310.692.8883, to discuss your rights free of charge. You can also reach us through the firm’s website at www.portnoylaw.com, or by email at info@portnoylaw.com.
If you choose to take no action, you can remain an absent class member.
Joining the case through the Portnoy Law website enables investors to learn about their legal claims and take an active role in recovering their losses.
The Portnoy Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
CONTACT:
Portnoy Law Firm
Lesley F. Portnoy, Esq.,
www.portnoylaw.com
Office: 310.692.8883
1800 Century Park East, Suite 600
Los Angeles, CA 90067
info@portnoylaw.com
BioVie, a clinical-stage biopharmaceutical company, focuses on developing drug therapies for neurological, neurodegenerative, and advanced liver diseases. The company acquired assets from NeurMedix and Acuitas, including NE3107, aimed at treating Alzheimer’s and Parkinson’s diseases. However, the complaint alleges that during the Class Period, BioVie made false and misleading statements about its operations and prospects. These included underestimating the impact of COVID-19 on clinical trials, protocol deviations, and non-compliance with Good Clinical Practice (GCP), leading to suspect data and significant non-compliance issues at trial sites.
The company admitted to potential scientific misconduct and GCP non-compliance in its 1Q 2023 report, significantly affecting stock prices. Following the disclosure of these issues, BioVie’s stock price plummeted, resulting in significant investor losses. The complaint highlights the company’s failure to provide accurate information regarding its clinical trials and compliance, impacting its stock market valuation and investor trust.
